| Identification | Back Directory | [Name]
VU6005649 | [CAS]
2137047-43-7 | [Synonyms]
CS-2729
VU6005649
VU-6005649;VU 6005649
VU6005649; VU-6005649; VU 6005649
Pyrazolo[1,5-a]pyrimidine, 3-(2,3-difluoro-4-methoxyphenyl)-2,5-dimethyl-7-(trifluoromethyl)- | [Molecular Formula]
C16H12F5N3O | [MDL Number]
MFCD31922705 | [MOL File]
2137047-43-7.mol | [Molecular Weight]
357.28 |
| Chemical Properties | Back Directory | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [form ]
Solid | [pka]
-1.73±0.30(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
VU 6005649, is a novel mGlu7/8 receptor agonist with excellent CNS penetration (Kp 1.9-5.8 and Kp,uu 0.4-1.4). | [in vivo]
When VU6005649 (compound 9f) is dosed at 30 mg/kg IP in 10% Tween 80/H2O (0.75 mg/kg. s.c. amphetamine), no efficacy is observed in this assay. VU6005649 shows modest but significant pro-cognitive effects on associative learning in wild-type mice and the first example of efficacy of an mGlu7/8 positive allosteric modulator (PAM) in this model[1]. | [IC 50]
mGlu7 Receptor: 0.65 μM (EC50); mGlu8 Receptor: 2.6 μM (EC50) | [storage]
Store at -20°C |
|
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
|